8-K: Fortrea Reports Q2 2026 Results, Raises Full-Year Guidance

Fortrea Holdings Inc. announced its second quarter 2026 financial results, reporting $678.2 million in revenue and increasing its full-year guidance.

Summary

• Fortrea Holdings Inc. reported second quarter 2026 revenue of $678.2 million, a decrease from $710.3 million in the second quarter of 2025.
• The company reported a GAAP net loss of $(13.2) million, or $(0.14) per diluted share, an improvement from a net loss of $(374.9) million in Q2 2025.
• Adjusted net income was $22.7 million, or $0.23 per diluted share, up from $17.6 million ($0.19 per diluted share) in Q2 2025.
• Adjusted EBITDA for the quarter was $58.7 million, an increase from $54.9 million in Q2 2025.
• The company's backlog stood at $7,800 million as of June 30, 2026.
• The book-to-bill ratio for the quarter was 1.06x, and 1.12x for the trailing 12 months.
• Fortrea has raised its full-year 2026 guidance to target revenues between $2,620 million and $2,690 million, and adjusted EBITDA between $205 million and $220 million.
• David Smith has been appointed Interim Chief Financial Officer, replacing Jason Knoblauch who is on a paid leave of absence due to pending litigation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with the increase in full-year guidance and improved operational metrics being key positives, offset by a slight revenue decline and the significant disruption caused by the CFO's leave of absence.

Positives

• Fourth consecutive quarter with a book-to-bill ratio above 1.0x.
• Full-year 2026 guidance has been increased.
• Improved GAAP net loss compared to the prior year's second quarter ($13.2 million loss vs. $374.9 million loss).
• Increased adjusted net income and adjusted diluted EPS compared to Q2 2025.
• Increased adjusted EBITDA compared to Q2 2025 ($58.7 million vs. $54.9 million).
• Positive cash flow from operations of $28.9 million for the quarter.
• Positive free cash flow of $19.9 million for the quarter.

Negatives

• Revenue decreased to $678.2 million in Q2 2026 from $710.3 million in Q2 2025.
• The company reported a GAAP net loss of $(13.2) million for the quarter.
• Jason Knoblauch, the Chief Financial Officer appointed on July 6, 2026, has been placed on a paid leave of absence due to pending litigation.

Risks

• The company's dependence on third parties for critical services.
• Risks and expenses associated with international operations, including tariffs, trade sanctions, and currency fluctuations.
• Customer or therapeutic area concentrations.
• Risks related to the adoption and use of technology, and the potential for negative effects or failure to capture anticipated benefits.
• The outcome and impact of pending or future litigation.
• Deterioration in the macroeconomic environment, particularly within the pharmaceutical and biotechnology industry.
• Changes in government regulations and funding that could lead to customer defaults or cancellations.
• The risk that backlog and net new business may not grow as anticipated or be indicative of future revenues.

Future Outlook

The company has increased its full-year 2026 guidance, targeting revenues in the range of $2,620 million to $2,690 million and adjusted EBITDA in the range of $205 million to $220 million.

Management Comments

• "Our second quarter results reflect continued progress against our strategy and disciplined execution across the business."
• "We delivered solid operating and financial performance, including our fourth consecutive quarter with a book-to-bill ratio above 1.0x, and raised our full-year 2026 guidance to reflect our confidence in the business."
• "Underlying this performance is the dedication of our teams around the world, who continue to build trusted partnerships with clients and help advance important therapies for patients."
• "We remain focused on commercial execution, operational excellence and financial discipline as we continue our strategic journey toward sustainable growth and margin expansion."

Industry Context

StockSavvy.ai notes that Fortrea's performance, particularly its increased guidance and consistent book-to-bill ratio, aligns with a positive trend in the contract research organization (CRO) sector, which benefits from increased outsourcing by pharmaceutical and biotechnology companies seeking to accelerate drug development.

Comparison to Industry Standards

• Fortrea's book-to-bill ratio of 1.06x for Q2 2026 and 1.12x for the trailing twelve months indicates healthy demand for its services, which is generally above the industry average for CROs experiencing stable to growing market conditions.
• The company's focus on operational excellence and margin expansion is a key strategic imperative for CROs aiming to compete with larger players like IQVIA and PPD (now part of Thermo Fisher Scientific), which often leverage scale for efficiency.
• The improvement in GAAP net loss compared to the prior year, despite a revenue decrease, suggests better cost management and a reduction in significant one-time charges (like the goodwill impairment in Q2 2025), a positive sign for profitability trends in the sector.

Management Changes

Legal Proceedings

• Jason Knoblauch, the CFO, is on a paid leave of absence due to a lawsuit filed by his prior employer alleging violation of restrictive covenants and retention of confidential information. A temporary restraining order was issued on July 25, 2026, preventing him from working as CFO pending further court order.

Stakeholder Impact

• Shareholders: Potential positive impact from increased full-year guidance and improved operational metrics, but tempered by the disruption of the CFO's departure and ongoing litigation.
• Employees: Continued focus on operational execution and team dedication is highlighted, suggesting a stable internal environment despite leadership changes.
• Clients: Continued partnerships and advancement of therapies are emphasized, indicating a commitment to client service.
• Creditors: Improved cash flow and EBITDA may be viewed positively, though the CFO situation could introduce uncertainty.

Next Steps

• Continue to focus on commercial execution, operational excellence, and financial discipline.
• Pursue sustainable growth and margin expansion.
• The company will file an offer letter for David Smith's interim CFO role with its Form 10-Q for the quarter ending September 30, 2026.

Key Dates

Recommendation

The company is showing operational improvements and has raised guidance, which are positive signs. However, the sudden departure of the CFO due to litigation introduces significant uncertainty and risk that warrants a cautious 'hold' stance until the legal situation is resolved and a permanent CFO is in place.

Keywords

Contract Research Organization, Clinical Development, Pharmaceutical Services, Biotechnology, Financial Results, Guidance, CRO, Drug Development